SCHEMBL21966922

SCHEMBL21966922

COc1cc(F)ccc1NC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.40
NPSR1 Q6W5P4 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
LMNA P02545 2/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 2/20 0.39
HTT P42858 4/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CCNE2 O96020 1/20 0.39
CCNE1 P24864 1/20 0.39
CDK2 P24941 1/20 0.39
KDM4E B2RXH2 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
USP2 O75604 1/20 0.38
FGFR1 P11362 1/20 0.38
FLT1 P17948 1/20 0.38
KDR P35968 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21965378 0.79 ALDH1A1 (0.56) MAPTNPSR1CYP1A2LMNAALDH1A1
SCHEMBL31029942 0.79 CYP1A2 (0.41) MAPTCYP1A2CYP3A4CYP2C19LMNA
SCHEMBL9232918 0.79 APP (0.51) MAPTCYP1A2CYP3A4CYP2C19LMNA
SCHEMBL29544483 0.78 MAPT (0.47) MAPTNPSR1LMNAALDH1A1GAA
SCHEMBL19194276 0.78 DDB1 (0.41) MAPTNPSR1CYP1A2CYP3A4CYP2C19
SCHEMBL21965773 0.78 TRPV4 (0.47) MAPTNPSR1ALDH1A1GAAMEN1
SCHEMBL11404084 0.77 CYP1A2 (0.45) MAPTCYP1A2CYP3A4CYP2C19LMNA
SCHEMBL22838172 0.77 MAPT (0.44) MAPTCYP1A2CYP3A4CYP2C19LMNA
SCHEMBL3232090 0.77 CYP1A2 (0.42) MAPTCYP1A2CYP3A4CYP2C19LMNA
SCHEMBL1513728 0.76 MAPT (0.59) MAPTNPSR1LMNAALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279023-A1 N/O-Linked Degrons and Degronimers for Protein Degradation C4 THERAPEUTICS, INC. (US) 2023-09-07 US disclosed
US-20230279023-A1 N/O-Linked Degrons and Degronimers for Protein Degradation C4 THERAPEUTICS, INC. (US) 2023-09-07 US disclosed
US-20200140456-A1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2020-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279023-A1 N/O-Linked Degrons and Degronimers for Protein Degradation CRBN, CBL, STUB1 MAPT 3822/4885NPSR1 1950/4885CYP1A2 4609/4885
US-20200140456-A1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION CRBN, CBL, STUB1 MAPT 3822/4885NPSR1 1950/4885CYP1A2 4609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.